查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445543

特发性膜性肾病变(IMN)市场评估:类型（苯丁酸氮芥、烷化剂、环磷□胺等）、应用（诊所、医院、其他）地区划分机会和预测-2017-2031

Idiopathic Membranous Nephropathy (IMN) Market Assessment, By Type [Chlorambucil, Alkylating Agents, Cyclophosphamide, Others], By Application [Clinics, Hospitals, Others], By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5个工作天内

价格

2024-2031年预测期内，全球特发性膜性肾病变（IMN）市场规模将以8.83%的复合年增长率增长，从2023年的2.014亿美元增长至2023年的3.9618亿美元。

人们对 IMN 的认识不断提高，以及政府为提高诊断解决方案的可负担性而采取的举措，正在为市场创造有利的成长机会。 这导致越来越多的研究努力确定 IMN 患者联合治疗的趋势，这已成为一个重要的市场趋势。 人口老化、久坐生活方式的增加以及肾臟疾病发病率的上升进一步推动了市场需求。

政府措施的增加支持市场成长

各政府机构加强支持研发活动，为市场创造了利润丰厚的成长机会。 已经进行了各种研究以确定药物对不同 IMN 患者的有效性。

增加研发活动支持市场发展

研发活动有多种好处，包括促进创新、加速新产品的开发、提高现有产品的有效性。 研究人员也正在研究联合疗法的效果。 中国北京协和医院正在进行一项干预研究，以探讨 RTX 与环孢素联合治疗 IMN 是否比单独使用 RTX 更有效。 IMN 的第一线免疫抑制治疗包括利妥昔单抗 (RTX) 或环磷□胺和皮质类固醇的组合，因为它们具有出色的安全性。 然而，利妥昔单抗单药治疗的长期缓解率约为60%。 由于环孢素和RTX对足细胞和免疫系统的影响不同，作用时间也不同，因此在特发性膜性肾病变的治疗中有望发挥协同作用。

北美占较大市占率

预计北美地区在预测期内将占据市场的主要份额。 这种增长归因于各种大型进入者的强劲存在以及该地区各个研究机构的研究活动的增加。 美国 NIAID 正在进行一项研究，评估静脉注射利妥昔单抗和贝利尤单抗与单一利妥昔单抗相比，在 IMN 患者中诱导完全缓解的有效性。 这项干预研究调查了与单独使用利妥昔单抗治疗相比，使用利妥昔单抗和贝利尤单抗联合治疗特发性膜性肾病变是否能更有效地阻止对肾臟的免疫攻击。

本报告调查了全球特发性膜性肾病变(IMN) 市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区、行业结构和市场的详细分析。它总结了影响成长的因素、案例分析主要公司的研究、竞争格局和概况。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球特发性膜性肾病变 (IMN) 市场展望

  • 市场规模/预测
  • 依类型
    • 苯丁酸氮芥
    • 烷基化剂
    • 环磷酰胺
    • 其他
  • 依用途
    • 诊所
    • 医院
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章按地区划分的全球特发性膜性肾病变 (IMN) 市场展望

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依类型
  • 依用途
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Astellas Pharma Inc.
  • GlaxoSmithKline
  • Aspen Global Inc.
  • Baxter Healthcare Corporation
  • Mylan Pharmaceuticals Inc
  • Sigma-Aldrich Corporation
  • Merck & Co., Inc.

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11092

Global idiopathic membranous nephropathy (IMN) market is projected to witness a CAGR of 8.83% during the forecast period 2024-2031F, growing from USD 201.4 million in 2023 to USD 396.18 million in 2031. The growing awareness about idiopathic membranous nephropathy and rising government efforts to increase the affordability of diagnostic solutions are providing lucrative growth opportunities to the market. In line with this, research activities are increasingly being conducted to determine the effects of combination therapy in patients with idiopathic membranous nephropathy, which is acting as a crucial market trend. The market demand is further driven by an increasing aging population, growing adoption of a sedentary lifestyle, and rising rate of renal diseases.

Increasing research activities by different research institutions to understand the effects of different treatments in patients with idiopathic membranous nephropathy is further supporting the market expansion. For instance, Beijing Friendship Hospital is conducting an interventional, randomized, open controlled study to understand the influence of various treatment schemes on the cognitive status of patients suffering from idiopathic membranous nephropathy. The exploration of the possible pathophysiological mechanism is expected to be conducted with the help of brain magnetic resonance imaging technology. The study aims to provide a theoretical basis for enhanced prevention of cognitive impairment and clinical treatment scheme selection and more information about the clinical cognitive status of idiopathic membranous nephropathy. The study is expected to conclude in 2025.

Rising Government Efforts Support Market Growth

Increasing efforts by various government institutes to support research and development activities are providing lucrative growth opportunities to the market. Different research studies are being conducted to determine the efficacy of drugs in different patients with idiopathic membranous nephropathy. The National Natural Science Foundation of China is supporting different research activities for treating idiopathic membranous nephropathy. Various studies have been conducted to demonstrate the efficacy of drugs in patients suffering from idiopathic membranous nephropathy with high or moderate proteinuria, however, systemic comparison has yet to be confirmed. Therefore, a network meta-analysis was performed for comparing the efficacy of idiopathic membranous nephropathy treatments in patients with high and moderate proteinuria, while comparing the risk of adverse events with idiopathic membranous nephropathy regimens.

Increasing Research and Development Activities are Boosting the Market Expansion

Research and development activities offer various benefits, including facilitation of innovation and accelerated development of new products as well as aid in improving the efficacy of existing products. They also allow researchers to study the effects of combination therapy. For instance, Peking Union Medical College Hospital, Beijing, China is conducting an interventional study to determine whether RTX combined with cyclosporine is more effective than RTX alone for treating idiopathic membranous nephropathy. The first-line immunosuppressive therapy of idiopathic membranous nephropathy includes Rituximab (RTX) or cyclophosphamide in combination with corticosteroids due to their superior safety profile. However, the long-term remission rate of Rituximab monotherapy is about 60%. Cyclosporin and RTX are expected to have a synergistic effect for treating idiopathic membranous nephropathy as they have different effects on podocytes and the immune system and different time of action.

North America Accounts for Significant Market Share

North America is expected to account for a significant share of the market over the forecast period. This growth can be attributed to the strong presence of various leading market players and increasing research activities by different research organizations in the region. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) is conducting a study to evaluate the effectiveness of intravenous rituximab and belimumab at inducing complete remission as compared to just rituximab in patients suffering from idiopathic membranous nephropathy. In this interventional study, researchers will evaluate if treating idiopathic membranous nephropathy in combination with rituximab and belimumab will effectively block the immune attacks on kidney in comparison to rituximab alone. Rituximab works by decreasing B cells, they are known to have a role in membranous nephropathy. Upon the removal of these cells, the disease might become less active or even completely inactive. Belimumab works by changing the type of new B cells produced in the body and decreasing the B cells. Belimumab has received approval from the Food and Drug Administration (FDA) for treating systemic lupus erythematosus, whereas rituximab is approved for treating vasculitis, rheumatoid arthritis, and some types of cancer. Treating membranous nephropathy with a combination of rituximab and belimumab has previously not been studied, however the combination has been tested for treating other autoimmune diseases. The study is expected to reach completion in 2030.

Cyclophosphamide Expected to Witness Significant Expansion

Recent studies have shown that alternating glucocorticoid-cyclophosphamide is superior to rituximab for proteinuria remission. RI-CYCLO and STARMEN confirmed the efficacy of glucocorticoid-cyclophosphamide in patients suffering from high-risk membranous nephropathy. For treating high-risk patients, the 2021 KDIGO guidelines recommend initiation of immunosuppressive treatments with cyclophosphamide associated with steroids, calcineurin, or RTX. The only recommended option for treatment in very high-risk patients is corticosteroids plus cyclophosphamide. Potential new strategies for the treatment of idiopathic membranous nephropathy include the utilization of an induction phase with intravenous cyclophosphamide on a monthly basis or a combination of RTX with low-dose cyclophosphamide. These strategies showcased encouraging immunological remission and clinical results, with excellent safety profile.

Hospitals Account for Significant Market Share

Hospitals are expected to account for a significant market share as some patients often face life threatening and severe nephrotic syndrome even while the excretory renal functions are working normally. Various medical college hospitals are conducting studies to understand the effects of different immunosuppressive therapies in patients suffering from idiopathic membranous nephropathy, which is expected to create positive market opportunities. For instance, Peking Union Medical College Hospital, Beijing, China, is conducting an interventional study for comparing the twenty-four-month remissions in idiopathic membranous nephropathy by different immunosuppressive therapies. The investigators designed this study for comparing the efficacy of corticosteroids plus cyclophosphamide with rituximab in treating idiopathic membranous nephropathy. The study is estimated to reach completion in 2027.

Future Market Scenario (2024 - 2031F)

Different research activities are underway in various regions across the globe for determining the tolerability, safety, and efficacy of different treatments for idiopathic membranous nephropathy. For instance, Nagoya University, Nagoya, Japan is conducting an interventional study to confirm the safety and efficacy of intravenous administration of rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome. The clinical study is going to be double-blind, randomized, multi-center, and placebo controlled and is estimated to reach completion in December 2026. Furthermore, various biotech companies, including SynAct Pharma Aps, are also conducting different studies to evaluate the efficacy and pharmacokinetic effects of different treatments in patients with idiopathic membranous nephropathy.

Key Players Landscape and Outlook

Key participants in the idiopathic membranous nephropathy (IMN) market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., and GlaxoSmithKline. The market is expected to witness significant growth over the forecast period due to rising research and development activities by different market players and the conduct of several clinical trials.

Novartis AG, one of the leading pharmaceutical corporations, received positive results for their phase 3 trials for targeted factor B inhibitor iptacopan. The company plans on initiating discussions with the FDA to receive accelerated approval for iptacopan, whose target indications include idiopathic membranous nephropathy, C3 glomerulopathy, and atypical haemolytic uraemic syndrome.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Idiopathic Membranous Nephropathy (IMN) Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Chlorambucil
    • 4.2.2. Alkylating Agents
    • 4.2.3. Cyclophosphamide
    • 4.2.4. Others
  • 4.3. By Application
    • 4.3.1. Clinics
    • 4.3.2. Hospitals
    • 4.3.3. Others
  • 4.4. By Region
    • 4.4.1. North America
    • 4.4.2. South America
    • 4.4.3. Europe
    • 4.4.4. Asia-Pacific
    • 4.4.5. Middle East & Africa
  • 4.5. By Company Market Share (%), 2023

5. Global Idiopathic Membranous Nephropathy (IMN) Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Chlorambucil
      • 5.1.2.2. Alkylating Agents
      • 5.1.2.3. Cyclophosphamide
      • 5.1.2.4. Others
    • 5.1.3. By Application
      • 5.1.3.1. Clinics
      • 5.1.3.2. Hospitals
      • 5.1.3.3. Others
    • 5.1.4. United States*
      • 5.1.4.1. Market Size & Forecast
      • 5.1.4.1.1. By Value
      • 5.1.4.1.2. By Volume
      • 5.1.4.2. By Type
      • 5.1.4.2.1. Chlorambucil
      • 5.1.4.2.2. Alkylating Agents
      • 5.1.4.2.3. Cyclophosphamide
      • 5.1.4.2.4. Others
      • 5.1.4.3. By Application
      • 5.1.4.3.1. Clinics
      • 5.1.4.3.2. Hospitals
      • 5.1.4.3.3. Others
    • 5.1.5. Canada
    • 5.1.6. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Application
  • 6.3. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. F. Hoffmann-La Roche Ltd
  • 13.4. Astellas Pharma Inc.
  • 13.5. GlaxoSmithKline
  • 13.6. Aspen Global Inc.
  • 13.7. Baxter Healthcare Corporation
  • 13.8. Mylan Pharmaceuticals Inc
  • 13.9. Sigma-Aldrich Corporation
  • 13.10. Merck & Co., Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 2. Global Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 7. North America Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 8. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 9. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 10. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 12. United States Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 13. United States Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 14. United States Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 15. Canada Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 16. Canada Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 17. Canada Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 18. Canada Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 19. Mexico Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 20. Mexico Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 21. Mexico Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 22. Mexico Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 23. Europe Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 24. Europe Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 26. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 27. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 29. Germany Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Germany Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 31. Germany Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 32. France Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 33. France Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 34. France Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 35. France Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 36. Italy Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 37. Italy Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 38. Italy Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 39. Italy Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 40. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 41. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 42. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 43. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 44. Russia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 45. Russia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Russia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 47. Russia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 48. Netherlands Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 49. Netherlands Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 50. Netherlands Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 51. Netherlands Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 52. Spain Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 53. Spain Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 54. Spain Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 55. Spain Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 56. Turkey Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 57. Turkey Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 58. Turkey Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 59. Turkey Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 60. Poland Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 61. Poland Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 62. Poland Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 63. Poland Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 64. South America Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 65. South America Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 67. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 68. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 70. Brazil Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Brazil Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 72. Brazil Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 73. Argentina Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 74. Argentina Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 75. Argentina Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 76. Argentina Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 77. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 78. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 79. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 80. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 81. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 82. India Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 83. India Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 84. India Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 85. India Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 86. China Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 87. China Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 88. China Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 89. China Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 90. Japan Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 91. Japan Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Japan Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 93. Japan Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 94. Australia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 95. Australia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 96. Australia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 97. Australia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 98. Vietnam Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 99. Vietnam Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 100. Vietnam Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 101. Vietnam Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 102. South Korea Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 103. South Korea Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 104. South Korea Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 105. South Korea Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 106. Indonesia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 107. Indonesia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. Indonesia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 109. Indonesia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 110. Philippines Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 111. Philippines Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 112. Philippines Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 113. Philippines Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 114. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 115. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 116. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 117. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 118. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 120. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 121. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 122. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 123. UAE Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 124. UAE Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 125. UAE Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 126. UAE Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 127. South Africa Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 128. South Africa Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 129. South Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 130. South Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 131. By Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 132. By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 133. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023